2 Houston startups announce new execs to their leadership

short stories

Cart.com and Topl — two growing Houston startups — have made strategic appointments. Photos courtesy

A pair of Houston tech startups have recently announced new appointments to their leadership staff. An e-commerce company has a new chief people officer and a blockchain company named a new president to lead commercialization.

Meet Cart.com's new C-suite hire

Sara Patterson is a human resources veteran. Photo courtesy of Cart.com

Houston-based Cart.com, an end-to-end ecommerce services provider, appointed Sara Patterson as chief people officer. She will lead all aspects of the company's talent acquisition and employee experience of the fast-growing startup.

As the company grows its team and its ecommerce-as-a-service platform, it's Patterson job to forge a strong, unified culture and develop a compelling talent acquisition strategy to support continuing growth, according to a press release from Cart.com.

"Sara is one of the most accomplished and experienced HR leaders in the business. She has a real gift for talent management, and unrivaled expertise driving success for fast-growing companies across a wide range of industries," says Omair Tariq, CEO of Cart.com, in the release. "Her experience and dedication are exactly what we need as we forge a unified workforce to support our end-to-end ecommerce platform. After all, we aren't just growing our workforce at record speed. We're also building a unified culture and delivering incredible employee experiences to ensure that our entire team — from office workers to warehouse pickers — can stay laser-focused on our core goal of helping ecommerce brands to thrive."

She has three decades of experience in human resources, including serving as CPO of Lemonade, which included managing over 500 employees. She also worked as vice president of HR and head of talent management at Walmart eCommerce, which had more than 15,000 employees. She has also held senior leadership positions at Bonobos, Tribune Media, Conde Nast, Coach, and Gilt.

"People are the key to success for any growing company, and I'm thrilled to be joining one of the fastest-growing and most transformative companies in the ecommerce space," Patterson says in the release. "Cart.com's leaders have made it clear that they see a strong culture as the key to lasting success, and I couldn't agree more. I'm delighted to be joining such a talented team, and supporting their continuing mission to unlock scalable growth for ecommerce brands."

Here's who will lead commercialization for Topl

Tim Marx has transitioned from adviser to employee at Topl. Photo courtesy of Topl

Tim Marx has joined Topl as president, the company recently announced. Marx will lead Topl's commercialization efforts and scaling. He previously supported the blockchain company as adviser.

A Fulbright Scholar, Stanford MBA, and former Boston Consulting Group partner and managing director, Marx has consulted on the ground in more than 20 countries, including those of Latin America, Europe, and Asia. He will continue to support Baird Capital as a venture partner, which he has since 2018.

"My overall thesis for getting involved in Topl is that I finally saw a really solid business use case versus a classic solution looking for a problem to solve," Marx says.

To learn more about him, read his recent Topl team member blog.

Saranas closed its series B round this week. Photo courtesy of Saranas

Houston-based medical device company snags $12.8M in series B

following the money

A Houston company that's changing the game when it comes to early bleed detection has raised its next round of funding.

Saranas Inc. announced that it closed a $12.8 million series B investment led by Wisconsin-based Baird Capital, the venture capital and global private equity arm of Baird, a global company with a location in Houston. Austin-based S3 Ventures also supported the round.

The company will use the funds to continue its clinical trials, per a news release.

"We are pleased to announce this round of funding led by Baird Capital," says Saranas President and CEO James Reinstein in the release. "It underscores the importance of real-time monitoring of bleeding complications and our opportunity to accelerate the commercialization of Early Bird. We look forward to expanding our clinical evidence through prospective clinical trials and launching next generation products, including Bird on a Wire, to address a much broader range of endovascular procedures."

Saranas received FDA approval for its Early Bird Bleed Monitoring System in 2019, as well as began its clinical trials. The device is designed to detect and track bleeding complications related to endovascular procedures. These medical procedures treat problems, such as aneurysms, that affect blood vessels. Around 20 percent of patients suffer a bleeding complication during endovascular procedures, like transcatheter aortic valve replacement, endovascular aneurysm repair, and percutaneous hemodynamic support. According to the release, the Early Bird remains the first and only device of its kind.

"As the Saranas team will say, 'Bleeding happens, but complications don't have to,'" says Amy Len Kobe, principal with Baird Capital, in the release. "Baird Capital is proud to partner with Saranas to address bleeding complication challenges and provide solutions that improve outcomes and reduce costs for patients, physicians and providers. We are also pleased to invest in Houston, a growing ecosystem of healthcare innovation and a target market for Baird."

Baird has operated an office locally since 1985, and the venture group has a partnership with the Texas Medical Center since 2018.

S3 Ventures also has an established presence in Houston, and health care technology is one of the three verticals the fund focuses on.

"S3 is enthusiastic about Saranas' game-changing medical device advancements," says Brian R. Smith, managing director of S3 Ventures, in the release. "We invest in companies that are re-imagining the way the world works, lives and heals, and we believe Saranas is a perfect representation of this."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston edtech company closes oversubscribed $3M seed round

fresh funding

Houston-based edtech company TrueLeap Inc. closed an oversubscribed seed round last month.

The $3.3 million round was led by Joe Swinbank Family Limited Partnership, a venture capital firm based in Houston. Gamper Ventures, another Houston firm, also participated with additional strategic partners.

TrueLeap reports that the funding will support the large-scale rollout of its "edge AI, integrated learning systems and last-mile broadband across underserved communities."

“The last mile is where most digital transformation efforts break down,” Sandip Bordoloi, CEO and president of TrueLeap, said in a news release. “TrueLeap was built to operate where bandwidth is limited, power is unreliable, and institutions need real systems—not pilots. This round allows us to scale infrastructure that actually works on the ground.”

True Leap works to address the digital divide in education through its AI-powered education, workforce systems and digital services that are designed for underserved and low-connectivity communities.

The company has created infrastructure in Africa, India and rural America. Just this week, it announced an agreement with the City of Kinshasa in the Democratic Republic of Congo to deploy a digital twin platform for its public education system that will allow provincial leaders to manage enrollment, staffing, infrastructure and performance with live data.

“What sets TrueLeap apart is their infrastructure mindset,” Joe Swinbank, General Partner at Joe Swinbank Family Limited Partnership, added in the news release. “They are building the physical and digital rails that allow entire ecosystems to function. The convergence of edge compute, connectivity, and services makes this a compelling global infrastructure opportunity.”

TrueLeap was founded by Bordoloi and Sunny Zhang and developed out of Born Global Ventures, a Houston venture studio focused on advancing immigrant-founded technology. It closed an oversubscribed pre-seed in 2024.

Texas space co. takes giant step toward lunar excavator deployment

Out of this world

Lunar exploration and development are currently hampered by the fact that the moon is largely devoid of necessary infrastructure, like spaceports. Such amenities need to be constructed remotely by autonomous vehicles, and making effective devices that can survive the harsh lunar surface long enough to complete construction projects is daunting.

Enter San Antonio-based Astroport Space Technologies. Founded in San Antonio in 2020, the company has become a major part of building plans beyond Earth, via its prototype excavator, and in early February, it completed an important field test of its new lunar excavator.

The new excavator is designed to function with California-based Astrolab's Flexible Logistics and Exploration (FLEX) rover, a highly modular vehicle that will perform a variety of functions on the surface of the moon.

In a recent demo, the Astroport prototype excavator successfully integrated with FLEX and proceeded to dig in a simulated lunar surface. The excavator collected an average of 207 lbs (94kg) of regolith (lunar surface dust) in just 3.5 minutes. It will need that speed to move the estimated 3,723 tons (3,378 tonnes) of regolith needed for a lunar spaceport.

After the successful test, both Astroport and Astrolab expressed confidence that the excavator was ready for deployment. "Leading with this successful excavator demo proves that our technology is no longer theoretical—it is operational," said Sam Ximenes, CEO of Astroport.

"This is the first of many implements in development that will turn Astrolab's FLEX rover into the 'Swiss Army Knife' of lunar construction. To meet the infrastructure needs of the emerging lunar economy, we must build the 'Port' before the 'Ship' arrives. By leveraging the FLEX platform, we are providing the Space Force, NASA, and commercial partners with a 'Shovel-Ready' construction capability to secure the lunar high ground."

"We are excited to provide the mobility backbone for Astroport's groundbreaking construction technology," said Jaret Matthews, CEO of Astrolab, in a release. "Astrolab is dedicated to establishing a viable lunar ecosystem. By combining our FLEX rover's versatility with Astroport's civil engineering expertise, we are delivering the essential capabilities required for a sustainable lunar economy."

---

This article originally appeared on CultureMap.com.

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.

View All Listings